Cover News Reporter Zhu Ning
At the beginning of March, the inter-provincial Chinese medicine (material) purchasing alliance of Sanming Purchasing Alliance (National) was officially launched to collect and report the quantity of traditional Chinese medicine tablets. Some industry insiders revealed that the current data filling work has been completed. In accordance with established practice, late April or start enterprise registration, product bidding and quotation work, the fastest bid opening in mid to late May. This means that China's first cross-regional alliance Chinese medicine tablets collection curtain officially opened, more than 200 billion yuan of Chinese medicine tablets market or will accelerate the reorganization.
Carrying out the data reporting work of Chinese medicine tablets
March 10, Shanxi Province, the centralized bidding and purchasing center of medicines and equipment issued a letter, in accordance with the Sanming Purchasing Alliance (National) Office of the "on the part of Chinese medicine tablets varieties of the relevant data reporting work notice" requirements, the organization of Shanxi Province, medical institutions to carry out the centralized purchasing of Chinese medicine tablets in quantities. The Office of the Union (National) has organized medical institutions in Shanxi Province to carry out centralized band-volume procurement of Chinese medicinal tablets and to fill in the procurement data of the relevant varieties, and has encouraged the designated social-run medical institutions and designated pharmacies to participate in this centralized procurement voluntarily. In addition to Shanxi, Shandong, Ningxia and other places have also arranged for the Chinese medicine drink quantity work.
The notice makes it clear that medical institutions should report the historical purchase volume, total purchase amount, recent purchase unit price, manufacturer and specifications of catalog varieties one by one according to the procurement situation in 2021. If there are more than one manufacturer supplying the same variety, they should fill in the report one by one according to the name of the same variety.
According to the list of joint band purchasing of Chinese medicine tablets, the purchased varieties include 21 common tablets such as Astragalus, Codonopsis tablets and honeysuckle.
Chinese medicine tablets refers to the Chinese herbal medicines and their processed concoctions of Chinese herbal medicines that can be used directly for blending or preparation under the guidance of the theory of traditional Chinese medicine, which is one of the three pillars of China's traditional Chinese medicine industry, and the relevant data show that in 2018, the market size of China's traditional Chinese medicine tablets market alone has reached about 220 billion yuan, and it is expected that it will be more than 260 billion yuan in 2022.
But for a long time, the standardization of Chinese medicine tablets is difficult to unify, and the price is affected by the season, origin and other factors. There is some difficulty in organizing collective purchasing as in the case of proprietary Chinese medicines.
Chinese herbal medicine standardization problems constraints set mining
Reporters check the information found that in 2009-2010, ginseng, panax ginseng and ginseng and other core Chinese medicine industry raw materials in one year appeared to be nearly 10 times more than the upsurge; 2020 the second half of the year so far, forsythia, shengdi, and other bulk raw materials, the same appeared to double the rise in quotations and there is still a continuing upward trend.
And the collection of 21 varieties, the price of varieties rose during the year accounted for a relatively high proportion. 21 collection of varieties, rising varieties of 16, accounting for 76.19%; of which, the price rose more than 50% of the 7, including Chuanxiong, Chinese yam, Salvia divinorum, Mudanpi, Atractylodes macrocephala, Maitou and Angelica sinensis.
Why the price of Chinese herbs can appear so sharp fluctuations? With this question, the reporter found the operation of Chinese herbal medicine planting, acquisition and rough processing of Gansu Wo Sheng agricultural responsible person, Ms. Jiang, which said that the vast majority of Chinese herbs are agricultural by-products, or there is a "food by the sky" component.
Ms. Jiang said: "The production of Chinese herbal medicine is often affected by the rise and fall of the market of Chinese herbal medicine in the previous year, especially some high-yield varieties will become the first choice of farmers to plant and produce. Therefore, changes in the planting and production cycle of Chinese herbal medicines will also have a direct impact on future changes in the price of Chinese medicine."
And the most important thing to note is that part of the Chinese herbal medicine production recovery cycle takes 3-4 years, the planting difficulty is also relatively high, if for some reason suddenly surge in demand, then in one to two years time actually the market has no new supply of goods.
In the collection of varieties, such as maitake, salvia, these varieties, once the price continues to be low, the production of the production area is rapidly reduced, the contradiction between supply and demand is very easy to change; safflower, radix et rhizoma, angelica, if the origin of the rainfall is too much, it is easy to lead to poor plant growth, the decline in the capacity of the monoculture is obvious, which also results in a higher price of the product.
For the standardization of Chinese herbal medicines, Ms. Jiang said, from the perspective of the entire industry practitioners, we all hope that there will be a set of more reasonable standards appear, but in fact it is very difficult. The same species, in different geographical output from the chemical test results, the data gap is not large, but the market recognition and medical effects are not the same; secondly, even the same geographical area, different years, if there is some extreme weather, the output will be different.
Collective purchasing can improve the overall quality of Chinese medicine tablets
The reporter noted that the joint purchasing "Chinese medicine tablets joint volume purchasing varieties list", for the upcoming launch of the joint purchasing of Chinese medicine tablets, the publicity of the implementation of the standard, the description of the traits, the article number, specifications, and specifications of the grade. All of this is to solve a difficult problem "standardization".
But it should be noted that, Xu Tian emphasized that, once the tablets into the set of procurement, there may be a uniformity of specifications of tablets, price stabilization of the phenomenon, but in the see the good side also need to see the side of the pitfalls.
That collection in the integration of resources may appear monopoly raw material behavior. Previously, a number of Chinese medicine enterprises production and supply, the target is still relatively decentralized, raw materials are also easy to organize. And when the results of the bidding is concentrated in a few companies, the goal is more prominent, speculators are more likely to "manipulate" the core raw materials of the bidding products, such as some of the raw materials composed of a variety of compound varieties, if there is a cold back of the raw materials are in control of the production of the enterprise may be affected.
Finally, Xu Tian concluded that the collection and procurement of traditional Chinese medicine has become a trend, is expected to have a standardized role in the long-term development of the Chinese medicine industry, but we must pay attention to the specific operation of the market price is prone to fluctuations contrary to the fundamentals of the problem.
If you have news clues, welcome to report to us, once adopted there is a fee reward. Reporting WeChat attention: ihxdsb, reporting QQ: 3386405712